Clinical trials
Urothelial Cancer clinical trials
Below are recruiting urothelial cancer clinical trials, each written for real people, not researchers. We’re tracking 184 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07671092RecruitingEarly Phase 1
Imaging study for advanced cancers
This trial is testing a new imaging method to see if it can help find cancer that has spread in people with certain advanced cancers like bladder cancer, breast cancer, or lung cancer.
St Leonards, New South WalesAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT05754853RecruitingPhase 3
MRG002 antibody compared with standard chemo for HER2 bladder cancer
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07419295RecruitingPhase 3
Testing a new drug for advanced bladder cancer
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07441499Recruiting
Detecting bladder cancer recurrence with a blood test
This study uses a blood test to find and monitor urothelial cancer (a type of bladder cancer) and to watch for signs it may come back. It may help patients and doctors make better decisions about follow-up care.
TianjinAges 18 years+ - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT06138561Recruiting
Bladder cancer treatment study for older adults
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
Boston, MassachusettsAges 65 years+ - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT07232602RecruitingPhase 1/Phase 2
New drug combinations for advanced bladder cancer
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
San Francisco, CaliforniaAges 18 years+ - NCT04574960RecruitingPhase 3
Neoadjuvant chemotherapy before kidney/ureter cancer surgery
This Phase 3 trial studies giving cisplatin-based chemotherapy before surgery for certain newly diagnosed upper-urinary-tract urothelial cancers (kidney/ureter). It may help shrink the cancer and improve outcomes by treating microscopic disease earlier.
Ottawa, OntarioAges 18 years+ - NCT06026189Recruiting
Reducing cystoscopy for blood in urine
This trial tests if we can safely skip a bladder camera test (cystoscopy) for people who have microscopic blood in their urine. If you meet certain criteria, you may not need the procedure.
RotterdamAges Any age - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT06787053Recruiting
MRI imaging for oxygen-starved tumors
This study uses MRI scans to find areas of low oxygen in tumors and see if adjusting radiation treatment can help. It is open to adults with bladder, cervix, or prostate cancer who are getting radiation therapy at the Christie NHS Foundation Trust.
ManchesterAges 18 years+ - NCT04970472Recruiting
Urothelial bladder cancer sample collection for adults
This trial collects clinical samples from adults who have suspected or confirmed urothelial (bladder/urinary tract lining) cancer. It helps researchers study the disease and may support future improvements in diagnosis or treatment.
ToulouseAges 18–99 - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT05312671RecruitingPhase 2
Atezolizumab plus chemo for small cell bladder cancer
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT07848854RecruitingPhase 2
New imaging test to spot bladder cancer during surgery
This trial tests a special dye that binds to bladder cancer cells and makes them glow during surgery. It may help doctors find and remove the cancer more completely.
Kunming, YunnanAges 18–80 - NCT06696742RecruitingPhase 2
PD-1 inhibitor plus probiotic for bladder cancer
This trial tests a combination of a PD-1 inhibitor (which helps your immune system fight cancer) and a probiotic called Clostridium butyricum for people with bladder cancer. It is for those who either have invasive bladder cancer before surgery, or have high-risk features after surgery, and haven't had previous immunotherapy or chemotherapy.
Nanjing, JiangsuAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07855926Recruiting
Perioperative drug therapy for muscle-invasive bladder cancer
This study looks at different drug treatments given around the time of surgery for muscle-invasive bladder cancer. It aims to understand how well these treatments work and may help guide future care.
MunichAges 18 years+ - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urothelial cancer?
- Yes. Clin2 currently lists 184 recruiting urothelial cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urothelial cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urothelial cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.